This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MenACWY-TT, GSK134612, GSK 134612
Description: Nimenrix is a Neisseria meningitidis serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Pfizer and GlaxoSmithKline
In June 2015, Pfizer announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million. Pfizer is deemed, under Listing Rule 11.1.4R, to be a related party of GSK as a result of holdings of the Pfizer group in ViiV Healthcare. The sale is a smaller related party transaction under Listing Rule 11.1.10R (1) and has been agreed following a confirmation from GSKs sponsor that the terms of the sale are fair and reasonable as far as GSKs shareholders are concerned. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015.
In October 2015, Pfizer announced that it has completed the acquisition of GlaxoSmithKlines quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
Additional information available to subscribers only: